Evaxion A (EVAX) Long-Term Deferred Tax (2020 - 2025)
Evaxion A's (EVAX) quarterly Long-Term Deferred Tax came in at $23.2 million in Q4 2025, up 13.36% YoY from $20.4 million in Q4 2024, and up 13.36% on a QoQ basis from $20.4 million in Q4 2024.
Evaxion A (EVAX) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends
Evaxion A (EVAX) has 6 years of Long-Term Deferred Tax data on file, last reported at $23.2 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 13.36% year-over-year to $23.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.2 million (up 13.36% YoY) and the FY2025 annual result came in at $23.2 million, up 13.36% from the prior year.
- Long-Term Deferred Tax improved to $23.2 million in Q4 2025, from $20.4 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $23.2 million in Q4 2025 to a low of $10000.0 in Q1 2022.
- A 5-year average of $8.5 million and a median of $252000.0 in 2021 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax tumbled 94.41% — and 2023, when it soared 40.06%.
- Tracing EVAX's Long-Term Deferred Tax over 5 years: stood at $133000.0 in 2021, then jumped by 10111.28% to $13.6 million in 2022, then soared by 40.06% to $19.0 million in 2023, then advanced by 7.4% to $20.4 million in 2024, then climbed by 13.36% to $23.2 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $23.2 million (Q4 2025), $20.4 million (Q4 2024), and $19.0 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.16 Mn |
| Dec 31, 2024 | 20.43 Mn |
| Dec 31, 2023 | 19.02 Mn |
| Dec 31, 2022 | 13.58 Mn |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Sep 30, 2021 | 133,000.00 |
| Jun 30, 2021 | 252,000.00 |
| Mar 31, 2021 | 179,000.00 |
| Dec 31, 2020 | 262,000.00 |